All of DSpace

Browsing by Subject "European Respiratory Society"

Now showing items 1-12 of 12

    • Combined pulmonary fibrosis and emphysema characteristics in a Greek cohort 

      Malli F., Papakosta D., Antoniou K., Dimadi M., Polychronopoulos V., Malagari K., Oikonomou A., Bouros D.E., Daniil Z. (2019)
      Background: Combined pulmonary fibrosis and emphysema (CPFE) has recently received great attention, with studies suggesting that it presents a distinct clinical entity while others have challenged this hypothesis. This ...

    • Early COVID-19 lockdown in Greece and idiopathic pulmonary fibrosis: a beneficial “impact” beyond any expectation 

      Papiris S.A., Bouros D., Markopoulou K., Kolilekas L., Papaioannou A.I., Tzilas V., Tzouvelekis A., Fouka E., Papakosta D., Daniil Z., Steiropoulos P., Gogali A., Papanikolaou I.C., Xyfteri A., Haritou A., Korbila I., Tomos I.P., Loukides S., Bellelli R., Kounti G., Rampiadou C., Karampitsakos T., Dimeas I., Kirgou P., Bompoki A., Vasarmidi E., Loverdos K., Antonogiannaki E.-M., Blizou M., Bouros E., Kagouridis K., Maniati M., Karakatsani A., Antoniou K.M., Manali E.D. (2021)
      [No abstract available]

    • Efficacy and safety of nintedanib in a greek multicentre idiopathic pulmonary fibrosis registry: A retrospective, observational, cohort study 

      Antoniou K., Markopoulou K., Tzouvelekis A., Trachalaki A., Vasarmidi E., Organtzis J., Tzilas V., Bouros E., Kounti G., Rampiadou C., Kotoulas S.-C., Bardaka F., Bibaki E., Fouka E., Meletis G., Tryfon S., Daniil Z., Papakosta D., Bouros D. (2020)
      Nintedanib is a tyrosine kinase inhibitor approved for the treatment of idiopathic pulmonary fibrosis (IPF). In a retrospective, real-world study across seven Greek hospitals, we evaluated the effectiveness and safety of ...

    • Epidemiology of interstitial lung diseases and their progressive-fibrosing behaviour in six European countries 

      Hilberg O., Hoffmann-Vold A.-M., Smith V., Bouros D., Kilpeläinen M., Guiot J., Morais A., Clemente S., Daniil Z., Papakosta D., Fretheim H., Neves S., Alfaro T.M., Antoniou K.M., Valveny N., Asijee G., Soulard S., Wuyts W. (2022)
      The PERSEIDS study aimed to estimate incidence/prevalence of interstitial lung diseases (ILDs), fibrosing interstitial lung diseases (F-ILDs), idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated ILD (SSc-ILD), ...

    • ERS International Congress 2021: highlights from the Thoracic Surgery and Lung Transplantation Assembly 

      Bos S., Ricciardi S., Caruana E.J., Öztürk N.A.A., Magouliotis D., Pompili C., Migliore M., Vos R., Meloni F., Elia S., Hellemons M. (2022)
      The thoracic surgery and lung transplantation assembly of the European Respiratory Society (ERS) is delighted to present the highlights from the 2021 ERS International Congress. We have selected four sessions that discussed ...

    • ERS statement on obstructive sleep disordered breathing in 1- to 23-month-old children 

      Kaditis A.G., Alvarez M.L.A., Boudewyns A., Abel F., Alexopoulos E.I., Ersu R., Joosten K., Larramona H., Miano S., Narang I., Tan H.-L., Trang H., Tsaoussoglou M., Vandenbussche N., Villa M.P., Waardenburg D.V., Weber S., Verhulst S. (2017)
      The present statement was produced by a European Respiratory Society Task Force to summarise the evidence and current practice on the diagnosis and management of obstructive sleep disordered breathing (SDB) in children ...

    • Impact of the financial crisis on COPD burden: Greece as a case study 

      Kotsiou O.S., Zouridis S., Kosmopoulos M., Gourgoulianis K.I. (2018)
      Poverty and low socioeconomic status have been associated with chronic obstructive pulmonary disease (COPD). The current financial crisis has forced millions back into poverty. Greece is one of the countries hit the hardest, ...

    • Nasal high-flow oxygen versus noninvasive ventilation in acute exacerbation of copd: Protocol for a randomised noninferiority clinical trial 

      Papalampidou A., Bibaki E., Boutlas S., Pantazopoulos I., Athanasiou N., Moylan M., Vlachakos V., Grigoropoulos V., Eleftheriou K., Daniil Z., Gourgoulianis K., Kalomenidis I., Zakynthinos S., Ischaki E. (2020)
      Background: Noninvasive ventilation (NIV) is considered as the first-line treatment for acute exacerbation of COPD (AECOPD) complicated by respiratory acidosis. Recent studies demonstrate a role of nasal high-flow oxygen ...

    • Nebulised colistin for ventilator-associated pneumonia prevention 

      Karvouniaris M., Makris D., Zygoulis P., Triantaris A., Xitsas S., Mantzarlis K., Petinaki E., Zakynthinos E. (2015)
      We evaluated whether prophylactic nebulised colistin could reduce ventilator-associated pneumonia (VAP) rates in an intensive care unit (ICU) setting with prevalent multidrug-resistant (MDR) bacteria. We used a single-centre, ...

    • Obstructive sleep disordered breathing in 2- to 18-year-old children: Diagnosis and management 

      Kaditis A.G., Alvarez M.L.A., Boudewyns A., Alexopoulos E.I., Ersu R., Joosten K., Larramona H., Miano S., Narang I., Trang H., Tsaoussoglou M., Vandenbussche N., Villa M.P., Waardenburg D.V., Weber S., Verhulst S. (2016)
      This document summarises the conclusions of a European Respiratory Society Task Force on the diagnosis and management of obstructive sleep disordered breathing (SDB) in childhood and refers to children aged 2-18 years. ...

    • Prognostic assessment in COPD without lung function: The B-AE-D indices 

      Boeck L., Soriano J.B., Brusse-Keizer M., Blasi F., Kostikas K., Boersma W., Milenkovic B., Louis R., Lacoma A., Djamin R., Aerts J., Torres A., Rohde G., Welte T., Martinez-Camblor P., Rakic J., Scherr A., Koller M., Van Der Palen J., Marin J.M., Alfageme I., Almagro P., Casanova C., Esteban C., Soler-Cataluña J.J., De-Torres J.P., Miravitlles M., Celli B.R., Tamm M., Stolz D. (2016)
      Several composite markers have been proposed for risk assessment in chronic obstructive pulmonary disease (COPD). However, choice of parameters and score complexity restrict clinical applicability. Our aim was to provide ...

    • Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with idiopathic pulmonary fibrosis 

      Karampitsakos T., Papaioannou O., Dimeas I., Tsiri P., Sotiropoulou V., Tomos I., Papanikolaou I.C., Katsaras M., Kirgou P., Daniil Z., Gourgoulianis K.I., Sampsonas F., Manali E., Papiris S., Bouros D., Tzouvelekis A. (2022)
      [No abstract available]